ProCE Banner Activity

ASCEND-CML: Update From Phase II Trial of Frontline Asciminib in Patients With CP-CML

Conference Coverage
Slideset

Updated data from the phase II ASCEND-CML trial of frontline asciminib in patients with newly diagnosed CML in chronic phase demonstrated high cumulative incidence of molecular response with fewer AEs reported over time.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation